Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Dendreon Stock On Roll As Cell Therapy Hopes Revive 

 

Dendreon Stock On Roll As Cell Therapy Hopes Revive
Investor's Business Daily
As IBD reported last month, Dendreon's prostate-cancer treatment Provenge was the flagship commercial product in cell therapy, a budding field of medicine that promises to not just halt disease progress but regenerate healthy tissue without side effects.
See all stories on this topic »

 

Posted on 15-Jan-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: